On June 18, 2026 Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), reported that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) filing for adjuvant Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with chemotherapy in stage III deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colon cancer, a type of tumor characterized by high mutation rates. The FDA has granted Priority Review and is expected to make a decision on the approval by October 9, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This filing acceptance brings us closer to establishing adjuvant Tecentriq plus chemotherapy as a new standard of care for certain types of early colon cancer," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "The ATOMIC results demonstrate that Tecentriq plus chemotherapy can substantially reduce the risk of disease recurrence or death, helping more patients remain cancer-free following surgery."

"One in three patients with stage III colon cancer will relapse within five years, underscoring the need for new adjuvant treatment options," said Michael Sapienza, CEO, Colorectal Cancer Alliance. "This milestone represents a critical step toward a reality where treatment is tailored to a patient’s specific tumor biology from the very beginning, giving them a better chance of preventing a recurrence."

The application is based on the landmark ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to standard FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, determined by an immunohistochemistry test, such as the VENTANA MMR RxDx Panel. The 36-month disease-free survival was 86% for Tecentriq combined with FOLFOX6 compared with 76% in the FOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and FOLFOX6.

Colon cancer remains one of the world’s most common and deadliest tumors. Over one million people are diagnosed globally each year, and despite surgery and chemotherapy, approximately 30% of stage III patients relapse within five years. Approximately 15% of colon cancer patients present with dMMR/MSI-H tumors, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.

The ATOMIC study was sponsored by the National Cancer Institute (NCI) and conducted by the Alliance for Clinical Trials in Oncology in partnership with Genentech and the Arbeitsgemeinschaft Internistische Onkologie (AIO) group in Germany. It highlights Genentech’s commitment to working alongside leading academic groups to tackle some of the most challenging cancers.

About the ATOMIC study
ATOMIC (A021502, NCT02912559) is a Phase III, randomized, open-label, multicenter study investigating the addition of Tecentriq (atezolizumab) to FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomized 1:1 to receive either FOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or FOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS).

About Tecentriq (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations.

What are Tecentriq and Tecentriq Hybreza?

Tecentriq (atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) are prescription medicines used to treat:

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC).

Tecentriq or Tecentriq Hybreza may be used alone as a treatment for your lung cancer:
to help prevent your lung cancer from coming back after your tumor(s) has been removed by surgery and you have received platinum-based chemotherapy, and
you have stage 2 to stage 3A NSCLC (talk to your healthcare provider about what these stages mean), and
your cancer tests positive for "PD-L1".

Tecentriq or Tecentriq Hybreza may be used alone as your first treatment when your lung cancer:
has spread or grown, and
your cancer tests positive for "high PD-L1", and
your tumor does not have an abnormal "EGFR" or "ALK" gene.

Tecentriq or Tecentriq Hybreza may be used with the medicines bevacizumab, paclitaxel, and carboplatin as your first treatment when your lung cancer:
has spread or grown, and
is a type called "non-squamous NSCLC", and
your tumor does not have an abnormal "EGFR" or "ALK" gene.

Tecentriq or Tecentriq Hybreza may be used with the medicines paclitaxel protein-bound and carboplatin as your first treatment when your lung cancer:
has spread or grown, and
is a type called "non-squamous NSCLC", and
your tumor does not have an abnormal "EGFR" or "ALK" gene.

Tecentriq or Tecentriq Hybreza may be used alone when your lung cancer:
has spread or grown, and
you have tried chemotherapy that contains platinum, and it did not work or is no longer working.
If your tumor has an abnormal "EGFR" or "ALK" gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

Adults with a type of lung cancer called "extensive stage small cell lung cancer (SCLC)", which is SCLC that has spread or grown

Tecentriq or Tecentriq Hybreza may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment
Tecentriq or Tecentriq Hybreza may be used with the medicine lurbinectedin as maintenance treatment when your lung cancer:
has not progressed after first treatment with Tecentriq or Tecentriq Hybreza and the chemotherapy medicines carboplatin and etoposide.

Adults with a type of liver cancer called hepatocellular carcinoma (HCC). Tecentriq or Tecentriq Hybreza may be used with the medicine bevacizumab when your liver cancer:

has spread or cannot be removed by surgery, and
you have not received other medicines by mouth or injection through your vein (IV) to treat your cancer.

Adults with a type of skin cancer called melanoma. Tecentriq or Tecentriq Hybreza may be used with the medicines cobimetinib and vemurafenib when your melanoma:

has spread to other parts of the body or cannot be removed by surgery, and
has a certain type of abnormal "BRAF" gene. Your healthcare provider will perform a test to make sure this Tecentriq or Tecentriq Hybreza combination is right for you.

Adults and children (12 years of age and older), with a type of soft tissue tumor (cancer) called alveolar soft part sarcoma (ASPS). Tecentriq or Tecentriq Hybreza may be used when your sarcoma:

has spread to other parts of the body or cannot be removed by surgery.

Adults with a type of bladder cancer called muscle invasive bladder cancer (MIBC) that has spread into the muscle layer of the bladder but not to other parts of the body. Tecentriq or Tecentriq Hybreza may be used alone as a treatment for your bladder cancer:

to help prevent your bladder cancer from coming back after your bladder has been removed by surgery, and
small pieces of DNA from the tumor (called circulating tumor DNA [ctDNA]) were found in your blood, showing that cancer cells remain in the body (molecular residual disease). Your healthcare provider will perform a test to make sure that Tecentriq or Tecentriq Hybreza is right for you.

It is not known if Tecentriq Hybreza is safe and effective when used:

in children for the treatment of NSCLC, SCLC, HCC, melanoma or MIBC.

It is not known if Tecentriq is safe and effective when used:

in children younger than 2 years of age for the treatment of ASPS.
in children for the treatment of NSCLC, SCLC, HCC, melanoma or MIBC.

Important Safety Information

Who should not receive Tecentriq Hybreza?

Do not receive Tecentriq Hybreza if you are allergic to hyaluronidase or any of the ingredients in Tecentriq Hybreza

What is the most important information about Tecentriq and Tecentriq Hybreza?

Tecentriq and Tecentriq Hybreza can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during your treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems

cough
shortness of breath
chest pain

Intestinal problems

diarrhea (loose stools) or more frequent bowel movements than usual
stools that are black, tarry, sticky, or have blood or mucus
severe stomach-area (abdomen) pain or tenderness

Liver problems

yellowing of your skin or the whites of your eyes
severe nausea or vomiting
pain on the right side of your stomach area (abdomen)
dark urine (tea colored)
bleeding or bruising more easily than normal

Hormone gland problems

headaches that will not go away or unusual headaches
eye sensitivity to light
eye problems
rapid heartbeat
increased sweating
extreme tiredness
weight gain or weight loss
feeling more hungry or thirsty than usual
urinating more often than usual
hair loss
feeling cold
constipation
your voice gets deeper
dizziness or fainting
changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

decrease in your amount of urine
blood in your urine
swelling of your ankles
loss of appetite

Skin problems

rash
itching
skin blistering or peeling
painful sores or ulcers in your mouth or your nose, throat, or genital area
fever or flu-like symptoms
swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq or Tecentriq Hybreza. Call or see your healthcare provider right away for any new or worsening signs or symptoms, including:

Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles
Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight
Persistent or severe muscle pain or weakness, muscle cramps
Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

chills or shaking
itching or rash
flushing
shortness of breath or wheezing
dizziness
feeling like passing out
fever
back or neck pain

Rejection of a transplanted organ or tissue. Your healthcare provider should tell you what signs and symptoms you should report and monitor you depending on the type of organ or tissue transplant that you have had.

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Tecentriq or Tecentriq Hybreza. Your healthcare provider will monitor you for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. Your healthcare provider will check you for these problems during your treatment with Tecentriq or Tecentriq Hybreza. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment with Tecentriq or Tecentriq Hybreza if you have severe side effects.

Before you receive Tecentriq or Tecentriq Hybreza, tell your healthcare provider about all of your medical conditions, including if you:

have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
have received an organ or tissue transplant, including corneal transplant
have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
have received radiation treatment to your chest area
have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
are pregnant or plan to become pregnant. Tecentriq and Tecentriq Hybreza can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Tecentriq or Tecentriq Hybreza. Females who are able to become pregnant:
Your healthcare provider should do a pregnancy test before you start treatment with Tecentriq or Tecentriq Hybreza.
You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of Tecentriq or Tecentriq Hybreza.
are breastfeeding or plan to breastfeed. It is not known if Tecentriq or Tecentriq Hybreza passes into your breast milk. Do not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq or Tecentriq Hybreza.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

feeling tired or weak
decreased appetite
nausea
cough
shortness of breath

The most common side effects of Tecentriq Hybreza when used alone include:

feeling tired or weak
muscle or bone pain
cough
shortness of breath
decreased appetite

The most common side effects of Tecentriq and Tecentriq Hybreza when used in lung cancer with other anti-cancer medicines include:

feeling tired or weak
nausea
hair loss
constipation
diarrhea
decreased appetite

The most common side effects of Tecentriq and Tecentriq Hybreza when used in hepatocellular carcinoma (HCC) with bevacizumab include:

high blood pressure
feeling tired or weak
too much protein in the urine

The most common side effects of Tecentriq and Tecentriq Hybreza when used in melanoma with cobimetinib and vemurafenib include:

skin rash
joint, muscle, or bone pain
feeling tired or weak
liver injury
fever
nausea
itching
swelling of legs or arms
mouth swelling (sometimes with sores)
low thyroid hormone levels
sunburn or sun sensitivity

The most common side effect of Tecentriq and Tecentriq Hybreza when used alone in MIBC is:

urinary tract infection

Tecentriq and Tecentriq Hybreza may cause fertility problems in females, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of Tecentriq and Tecentriq Hybreza. Ask your healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq and Tecentriq Hybreza.

You may report side effects to the FDA at 1-800-FDA-1088 or View Source You may also report side effects to Genentech at 1-888-835-2555.

(Press release, Genentech, JUN 10, 2026, View Source [SID1234666538])

On June 10, 2026 Abeona therapeutics presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Abeona Therapeutics, JUN 10, 2026, View Source [SID1234666536])

On June 9, 2026 Parabilis Medicines, Inc. (the "Company") reported to have entered into a Stock Purchase Agreement (the "Purchase Agreement") with Regeneron Pharmaceuticals, Inc. ("Regeneron"), for the purchase of an aggregate of 4,166,666 shares (the "Shares") of its voting common stock, par value $0.0001 ("Common Stock"), at a per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share, through a private placement financing (the "Private Placement"), which took place concurrently with the IPO of the Company’s Common Stock. The Private Placement closed on June 11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Purchase Agreement, Regeneron is entitled to certain piggyback registration rights. The Purchase Agreement contains customary representations, warranties and agreements by the Company and Regeneron.

The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The representations, warranties and covenants contained in the Purchase Agreement were made solely for the benefit of the parties to thereto and may be subject to limitations agreed upon by the contracting parties. Accordingly, the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms thereof and not to provide investors with any other factual information regarding the Company or its business.

(Filing, Parabilis Medicines, JUN 9, 2026, View Source [SID1234666568])

On June 09, 2026 Parabilis Medicines, Inc. (Nasdaq: PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease, reported the pricing of its upsized initial public offering of 33,500,000 shares of its common stock at a price to the public of $20.00 per share. In addition, Parabilis has granted the underwriters a 30-day option to buy an additional 5,025,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Parabilis common stock is expected to begin trading on the Nasdaq Global Select Market on June 10, 2026 under the ticker symbol "PBLS". The offering is expected to close on or about June 11, 2026 subject to the satisfaction of customary closing conditions.

Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities are acting as active book-running managers for the offering. LifeSci Capital LLC is acting as a passive bookrunning manager for the offering.

In addition to the shares being sold in the initial public offering, Parabilis has agreed to sell 4,166,666 shares of its common stock at $18.00 per share, or 90% of the initial public offering price per share, in a concurrent private placement to Regeneron Pharmaceuticals, Inc. The sale of the shares of common stock in the concurrent private placement will not be registered under the Securities Act of 1933, as amended. The concurrent private placement is also expected to close on or about June 11, 2026, subject to the satisfaction of customary closing conditions. The closing of Parabilis’ initial public offering is not conditioned upon the closing of the concurrent private placement, but the closing of the concurrent private placement is conditioned upon the closing of the initial public offering.

The gross proceeds to Parabilis from the initial public offering, before deducting underwriting discounts and commissions and offering expenses payable by Parabilis, are expected to be $670 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. In addition, Parabilis expects to receive proceeds of approximately $75 million from the sale of shares of common stock in the concurrent private placement. All of the shares of common stock are being offered by Parabilis.

Registration statements relating to the offering have been filed with the Securities and Exchange Commission (the "SEC") and became effective on June 9, 2026. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from the SEC’s website at www.sec.gov or from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, telephone: 1-800-808-7525, email: [email protected]; BofA Securities, Inc., Attn: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255-0001, email: [email protected]; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, telephone: (888) 474-0200, email: [email protected]; or Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, telephone: (212) 518-9544, email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Parabilis Medicines, JUN 9, 2026, View Source [SID1234666533])

On June 9, 2026 Treos Bio, a clinical-stage company developing off-the-shelf and personalized active cancer immunotherapies, reported three abstracts on its proprietary Promiscuous EPItopes (PEPI) Technology accepted for presentation at the European Association for Cancer Research (EACR) 2026 Congress in Budapest, June 8–11.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The lead clinical finding is from the OBERTO-101 trial in MSS mCRC, a tumor type that has historically responded poorly to currently available immunotherapy approaches. A patient treated with PolyPEPI1018 at Mayo Clinic in 2019 remains disease-free 77.2 months later, with pathological complete response confirmed across resected tissues, including liver lesions.

MSS disease represents the vast majority of colorectal cancer patients and remains one of the largest unmet needs in cancer immunotherapy. PolyPEPI1018 is TREOS Bio’s lead off-the-shelf multi-peptide immunotherapy candidate, already tested in three phase I/II clinical trials. If clinical efficacy continues to be demonstrated, its off-the-shelf design could offer important practical and commercial advantages compared with fully individualized approaches, including simpler logistics, faster treatment availability and broader scalability.

The presentations reinforce several elements of TREOS Bio’s strategy: advancing PolyPEPI1018 in MSS mCRC, demonstrating the potential of the PEPI platform to support target selection without requiring tumor biopsy, and extending the platform into additional difficult-to-treat cancers, including EGFR-mutant non-small cell lung cancer (NSCLC).

"These presentations highlight the potential of TREOS Bio’s PEPI Technology to support target prediction, broad T-cell activation and durable clinical benefit in difficult-to-treat cancers," said Sunjeet Sawhney, Chief Executive Officer of TREOS Bio. "They also reinforce the rationale for advancing PolyPEPI1018 in combination with standard therapies, while applying the PEPI Platform to additional immune-refractory cancers where current options remain limited."

OBERTO-101: Long-Term Pathological Complete Response in MSS mCRC
Co-authored by Dr. Mojun Zhu (Mayo Clinic), Dr. Joleen Hubbard (Allina Health Cancer Institute) and the Treos Bio scientific team, the case describes subject 01-0007: a patient with initially unresectable liver metastases plus lesions in the colon, lung and diffuse lymphadenopathy. After FOLFOX/cetuximab induction, the patient entered OBERTO-101 (NCT03391232) and received three doses of PolyPEPI1018 on top of standard fluoropyrimidine-based maintenance therapy. Tumor shrinkage led to partial response at week 36 and curative R0 surgery at week 56. Surgical pathology showed no viable tumor cells across the liver, colon and all 27 resected lymph nodes, and the patient remains disease-free.

Translational analyses documented broad immune activation, including:

T-cell responses against all seven PolyPEPI1018-targeted antigens;
Increases in tumor-infiltrating lymphocytes (CD3+ and CD8+ cells) after the third dose;
PolyPEPI1018-specific T-cell clonotypes detected in blood and tumor tissue, supporting intratumoral expansion of treatment-induced immune responses targeting non-mutated shared antigens in MSS mCRC.

EGFR-mutant NSCLC: Personalized Immunotherapy Followed by Tumor Regression on Sequential EGFR-TKI Therapy
A second case describes a 59-year-old with metastatic EGFR-mutant NSCLC and brain metastases, whose disease had progressed despite radiotherapy, EGFR-TKIs, chemotherapy and chemo-immunotherapy.

Under the German "individueller Heilversuch" regulatory framework, the patient received an 11-peptide personalized immunotherapy designed without tumor biopsy, using the patient’s HLA genotype and TREOS Bio’s PEPI Panel platform.

De novo T-cell responses against 7/11 peptides (no baseline responses);
Subsequent tumor RNA-sequencing confirmed expression of 8/11 predicted antigens;
After treatment, subsequent osimertinib produced sustained regression of lung and brain lesions, ongoing >9 months, with gene-expression signatures of an activated tumor microenvironment.

PEPI Panel: Rapid Target Selection Without Tumor Biopsy
The third abstract introduces the PEPI Panel, a library of 3,286 synthetic long peptides covering 184 shared tumor antigens across 19 indications. Built using proprietary data from more than 100,000 tumors and 15,693 HLA genotypes, the Panel is designed to identify peptide targets predicted to be immunogenic for individual patients using only a saliva or blood sample:

across 11 patients with seven tumor types, the PEPI Panel predicted approximately 70% of each patient’s top tumor-expressed antigens;
in 6 patients receiving PEPI-guided immunotherapies, 83% (60/72) of selected peptides induced T-cell responses.

PEPI Panel-based treatments can be designed in days, supporting a potentially faster and less invasive approach to personalized cancer immunotherapy.

(Press release, Treos Bio, JUN 9, 2026, View Source [SID1234666519])